Accessibility Menu
Emmaus Life Sciences logo

Emmaus Life Sciences(OTC) EMMA

Current Price$0.01
Market Cap$822.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-99%
1 Year-23%
1 Month-2%
Emmaus Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-23
Emmaus Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.22%USD 0.012026-07-16
1 month-2.38%USD 0.012026-06-23
3 month+31.62%USD 0.012026-04-24
Year to date-9.89%USD 0.012025-12-31
1 year-23.44%USD 0.022025-07-21
3 year-95.12%USD 0.242023-07-24
5 year-99.22%USD 1.502021-07-23
Since inception-99.88%USD 9.802019-07-18

Emmaus Life Sciences Financials at a Glance

Market Cap

$822.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.03M

Net Income (TTM)

-$8.50M

EPS (TTM)

-$0.13

P/E Ratio

-0.09

Dividend

$0.00

Beta (Volatility)

-0.58 (Low)

Price

$0.01

Volume

16,776

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.02

Estimated Earnings Date

Aug 17, 2026

EMMA News

Foolcom-Featured.png

Emmaus Sales Drop 48 Percent

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emmaus Life Sciences

Emmaus helps people with sickle cell disease manage painful episodes. Its main product, Endari, is a prescription powder for children and adults. The company also explores new cancer therapies for future use.

What’s in the Emmaus Medicine Cabinet?

  • Endari (73% of revenue): Prescription L-glutamine powder for sickle cell disease, used by adults and children aged five and older.
  • International Sales (25% of revenue): Endari distributed in the Middle East and North Africa through exclusive local partners.
  • Pipeline Therapies: Preclinical cancer drug (IRAK4 inhibitor) in partnership with Kainos Medicine, targeting solid tumors.
  • Metabolic Therapy Option: Exclusive rights to develop a new therapy for pancreatic cancer with a U.S. academic center.
  • Other Revenue (2%): Early access programs in Europe and minor licensing income.

Emmaus on the Move: Growth and Expansion

  • 2017: Endari received U.S. FDA approval for sickle cell disease.
  • 2022: Expanded Endari distribution to the Middle East and North Africa.
  • 2024: Lost U.S. market exclusivity as generics entered after Orphan Drug status expired.
  • 2025: Signed exclusive U.S. and Canada licensing deal with NeoImmuneTech for Endari distribution.
  • 2021: Entered preclinical partnership with Kainos Medicine for anti-cancer drug development.

Why Emmaus Is a Bit Different

Emmaus operates globally, selling through both exclusive and nonexclusive distributors. Its main product, Endari, is the only FDA-approved prescription L-glutamine for sickle cell disease. The company relies on strategic partnerships and real-world studies to support its market position.

Five Things You Need to Know

  • Net revenue was $12.5 million in 2025, down 25% from 2024.
  • Gross margin was 93% in 2025, with gross profit of $11.6 million.
  • Operating expenses fell 34% in 2025, reflecting cost-cutting measures.
  • Net loss was $7.5 million in 2025, up from $6.5 million in 2024.
  • Cash and cash equivalents were $2.1 million at year-end 2025.

Bottom Line

Emmaus has shifted from U.S. exclusivity to global partnerships and cost controls. The company faces financial pressure but continues to serve a rare disease market with a single approved product.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

33

CEO

Willis C. Lee

Website

www.emmausmedical.com

Headquarters

Torrance, CA 90503, US

EMMA Financials

Key Financial Metrics (TTM)

Gross Margin

93.35%

Operating Margin

3.22%

Net Income Margin

-70.65%

Return on Equity

13.78%

Return on Capital

N/A

Return on Assets

-45.45%

Earnings Yield

-11.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$822.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

70.19M

Volume

16.78K

Avg. Volume

46.81K

Financials (TTM)

Gross Profit

$11.23M

Operating Income

$387.00K

EBITDA

-$435.00K

Operating Cash Flow

-$634.00K

Capital Expenditure

-$1.00K

Free Cash Flow

-$635.00K

Cash & ST Invst.

$1.07M

Total Debt

$31.96M

Emmaus Life Sciences Performance Analysis

Emmaus Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 18,390,000-10.8%
20232023-12-31USD 29,597,00060.9%
20242024-12-31USD 16,653,000-43.7%
20252025-12-31USD 12,453,000-25.2%
Emmaus Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3017.1%
Q32025-09-3019.9%
Q42025-12-3114.0%
Q12026-03-31-48.5%
Emmaus Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.21-33.6%
20232023-12-31USD -0.07-67.3%
20242024-12-31USD -0.1045.1%
20252025-12-31USD -0.1214.7%
Emmaus Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3051.2%
Q32025-09-30-82.6%
Q42025-12-31-2.2%
Q12026-03-31-43.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.98M

-17.6%

Gross Profit

$1.81M

-16.8%

Gross Margin

91.52%

N/A

Market Cap

$822.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$24.18K

N/A

Employees

34

N/A

Net Income

-$3.34M

-43.1%

EBITDA

-$1.19M

-11.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.07M

-19.6%

Total Debt

$31.96M

-3.1%

Accounts Receivable

$2.05M

-0.6%

Inventory

$1.91M

+32.8%

Long Term Debt

$3.60M

+28.8%

Short Term Debt

$28.71M

-4.9%

Return on Assets

-45.45%

N/A

Return on Invested Capital

-0.75%

N/A

Free Cash Flow

-$344.00K

-223.3%

Operating Cash Flow

-$344.00K

-223.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SQZBSQZ Biotechnologies Company
$0.02+0.00%
HXBMHelix BioMedix, Inc.
$1.79+0.00%
BPTHBio-Path Holdings, Inc.
$0.04+0.00%
VPROViropro Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About EMMA

What is the current price of Emmaus Life Sciences?

Emmaus Life Sciences is trading at $0.01 per share.

What is the 52-week range for Emmaus Life Sciences?

Over the past 52 weeks, Emmaus Life Sciences has traded between $0.01 and $0.02.

How much debt does Emmaus Life Sciences have?

As of the most recent reporting period, Emmaus Life Sciences reported total debt of $31.96M.

How much cash does Emmaus Life Sciences have on hand?

Emmaus Life Sciences reported $1.07M in cash and cash equivalents in its most recent financial results.

What is Emmaus Life Sciences’s dividend yield?

Emmaus Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services